Dyne Therapeutics soars on positive trial results in DMD

Shares of Massachusetts, USA-based muscle specialist Dyne Therapeutics (Nasdaq: DYN) closed up almost 28% at $35.38 yesterday, after it released positive clinical data from its ongoing Phase I/II ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its ongoing Phase I/II DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.

New data from both trials demonstrated compelling impact on key disease biomarkers as well as improvement in multiple functional endpoints and favorable safety profiles.

Dyne also proposed to raise a $300-million follow-on. The firm closed a similarly hefty offering in January, raising $345 million after reporting early data from the Phase I/II DELIVER and ACHIEVE studies that first put its dystrophy therapies on the map earlier this year.